Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered

Phase 1

Completed

• Conditions: Alzheimer Disease
• Interventions: Drug: SAM-531

• Registration Number: NCT00745576
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The purpose of this study is to evaluate the effects of multiple doses of verapamil on the plasma concentration of a single dose of SAM-531 in healthy young adult subjects and to assess the safety and tolerability of co-administration of SAM-531 and verapamil.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-09-02
• Study First Submitted QC: 2008-09-02
• Study First Posted: 2008-09-03
• Study Start: 2008-10
• Primary Completion: 2008-12
• Study Completion: 2008-12
• Status Verified: 2010-02
• Last Update Submitted: 2010-02-05
• Last Update Posted: 2010-02-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 14

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	SAM-531	-

Primary Outcome Measures

Name	Time	Method
blood samples	7 weeks

Secondary Outcome Measures

Name	Time	Method
Safety based on supine vital signs evaluations, 12-lead ECGs and routine lab tests	7 weeks